|
Wednesday, November 15, 2017
Print Current Session:
 |
|
|
Wednesday
SESSION 31:
MEDICAL TREATMENTS; LIPID MANAGEMENT BY DRUGS; HEART AND CORONARY STENT RELATED TOPICS
Location: Grand Ballroom West, 3rd Floor
Moderators:Russell H. Samson, MD, RVT, FACS / Karthikeshwar Kasirajan, MD |
|
| SESSION 31 SCHEDULE | |
| 6:40 AM - 6:45 AM | Value And Limitations Of Cannabis (Marijuana) In Vascular Patients: What Is The Drug’s Effect On Blood Vessels |
|
Presenter(s):Karthikeshwar Kasirajan, MD Location: Grand Ballroom West, 3rd Floor |
|
| View Slides in PDF | |
| 6:46 AM - 6:51 AM | How Does A Cardiology Evaluation Before Major Vascular Surgery Decrease Perioperative Myocardial Infarction Rates |
|
Presenter(s):Ashraf Mansour, MD Location: Grand Ballroom West, 3rd Floor |
|
| View Slides in PDF | |
| 6:52 AM - 6:57 AM | Value Of Statins, Diet, Ezetimibe And PCSK-9 Inhibitors In Vascular Patients: Update On The Importance Of LDL Cholesterol (LDL-C) Levels: How Low Should They Be Pushed: What Drugs And Dosages |
|
Presenter(s):Peter Henke, MD Location: Grand Ballroom West, 3rd Floor |
|
| View Slides in PDF | |
| 6:58 AM - 7:03 AM | Are LDL-C Levels And Statin Induced Decreases In LDL-C Levels Important (As In Europe) Despite AHA Guidelines: How To Treat Patients Needing Lipid Lowering Who Appear Statin Intolerant |
|
Presenter(s):Caron B. Rockman, MD / Jeffrey S. Berger, MD, MS, FAHA, FACC Location: Grand Ballroom West, 3rd Floor |
|
| View Slides in PDF | |
| 7:04 AM - 7:09 AM | DEBATE: Lowering LDL-C Levels With Statins And PCSK-9 Inhibitors In Vascular And At Risk Patients Prevents Cardiovascular Events And Deaths, Is Reasonably Safe And Helps Patients To Have Longer And Better Lives |
|
Presenter(s):Ron Waksman, MD Location: Grand Ballroom West, 3rd Floor |
|
| View Slides in PDF | |
| 7:10 AM - 7:15 AM | DEBATE: Not So: Statins Are Dangerous Drugs And Lowering LDL-C Levels Does No Good And May Be Harmful |
|
Presenter(s):Sherif A.H. Sultan, MD, FRCS, EBQS-VASC Location: Grand Ballroom West, 3rd Floor |
|
| View Slides in PDF | |
| 7:16 AM - 7:21 AM | Why Are PCSK-9 Inhibitors A Game-Changer For PAD Patients: Coronary Plaques Can Stabilize With Lower LDL-C Levels Produced By High Dose Statins Plus PCSK-9 Inhibitors: The GLAGOV Trial: How Low Should The LDL-C Be Lowered To |
|
Presenter(s):Ido Weinberg, MD, MSc Location: Grand Ballroom West, 3rd Floor |
|
| View Slides in PDF | |
| 7:22 AM - 7:27 AM | The Less Than Stellar 3-Year Results Of The Absorb Drug Eluting Bioresorbable Stent (BRSs) (Abbott) In Coronary Lesions May Be Due To Variable And Imperfect Implantation Techniques And Sizing: Small Arteries May Be A Problem: What Is The Future For BRSs |
|
Presenter(s):Ron Waksman, MD / Gregg W. Stone, MD Location: Grand Ballroom West, 3rd Floor |
|
| View Slides in PDF | |
| 7:28 AM - 7:33 AM | Update On When If Ever After A Coronary BMS Or DES Can Vascular Surgery Safely Be Performed And How Should Antiplatelet Drugs Be Managed Perioperatively In Coronary Stent Patients |
|
Presenter(s):Caron B. Rockman, MD / Jeffrey S. Berger, MD, MS, FAHA, FACC Location: Grand Ballroom West, 3rd Floor |
|
| View Slides in PDF | |
| 7:34 AM - 7:39 AM | Effect Of Frailty Assessment On Preoperative Risk Predictive Models For Various Vascular Surgical Procedures In Various Vascular Beds |
|
Presenter(s):Mohammad H. Eslami, MD, MPH Location: Grand Ballroom West, 3rd Floor |
|
| View Slides in PDF | |
| 7:40 AM - 7:48 AM | Panel Discussion |
| END OF SESSION 31 | |
| previous | next |